Marta Montero

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

Adam Trickey, Margaret May, Jörg Janne Vehreschild et al. · The Lancet HIV · 2017 · 1.1K citations · Full text

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 371 citations · Full text

Hiv/aids Counselling, Treatment And Prevention, Week 48 +14

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

José Ramón Arribas, Pierre‐Marie Girard, Roland Landman et al. · The Lancet Infectious Diseases · 2015 · 142 citations · Full text

Hiv/aids Counselling, Human Retrovirus, Antiviral Drug Development +9

Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy

Adam Trickey, Margaret May, Jörg Janne Vehreschild et al. · PLoS ONE · 2016 · 114 citations · Full text

Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

Sergio Serrano‐Villar, Javier Martínez‐Sanz, Raquel Ron et al. · The Lancet HIV · 2020 · 68 citations · Full text

Primary Immunodeficiency, Treatment And Prevention, Human Retrovirus +9